These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4041136)

  • 21. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
    Guastalla JP; Vermorken JB; Wils JA; George M; Scotto V; Nooij M; ten Bokkel Huinnink WW; Dalesio O; Renard J
    Eur J Cancer; 1994; 30A(1):45-9. PubMed ID: 8142163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
    Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of intra-arterial and intravenous cisplatin on both limb tumor and lung metastases of transitional cell carcinoma RBT-1 in rats.
    Iwamoto Y; Sugioka Y
    Chemotherapy; 1990; 36(4):294-9. PubMed ID: 2253498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irreversible renal failure after intraperitoneal cisplatin administration. A case report.
    Gouge SF; Tietjen DP; Moore J
    J Reprod Med; 1989 Nov; 34(11):931-3. PubMed ID: 2585396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II).
    Daoud SS
    Cancer Chemother Pharmacol; 1994; 33(4):307-12. PubMed ID: 8281624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
    Bespalov VG; Vyshinskaya EA; Vasil'eva IN; Semenov AL; Maidin MA; Barakova NV; Stukov AN
    Bull Exp Biol Med; 2017 Jan; 162(3):383-386. PubMed ID: 28091920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intraperitoneal chemotherapy for ovarian adenocarcinoma: pharmacokinetics of cisplatin].
    Ravina JH; Szyller A; Mintz P; Ferrand S; Ciraru-Vigneron N; Zylberberg B; Bourdon R; Galliot M
    J Gynecol Obstet Biol Reprod (Paris); 1992; 21(2):193-7. PubMed ID: 1583298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of intraperitoneal cisplatin.
    Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
    Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro studies on the antitumor effect of cis-diamminedichloroplatinum II (cisplatin) against ovarian adenocarcinoma cell line of the rat].
    Sekiya S; Iwasawa H; Takamizawa H; Sugita M; Tenjin Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1982 Sep; 34(9):1487-90. PubMed ID: 6890087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
    Markman M
    Int J Gynecol Cancer; 2008; 18 Suppl 1():36-9. PubMed ID: 18336398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.
    Bespalov VG; Alvovsky IK; Tochilnikov GV; Stukov AN; Vyshinskaya EA; Semenov AL; Vasilyeva IN; Belyaeva OA; Kireeva GS; Senchik KY; Zhilinskaya NT; Von JD; Krasilnikova LA; Alexandrov VA; Khromov-Borisov NN; Baranenko DA; Belyaev AM
    Int J Hyperthermia; 2018 Aug; 34(5):545-550. PubMed ID: 28893108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.
    Howell SB; Pfeifle CE; Wung WE; Olshen RA
    Cancer Res; 1983 Mar; 43(3):1426-31. PubMed ID: 6681730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
    Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
    J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
    Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
    Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
    Markman M
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.